The experts reached 75% consensus for dose tapering of TPO-RA regimens with possible discontinuation for individual ITP patients achieving sustained platelet counts above 50 × 109/L (i.e., partial response [PR]) and 87.5% consensus for dose tapering above 100 × 109/L (i.e., complete response, CR), and no bleeding for at least 12 months with TPO-RAs in the absence of other concomitant treatments. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.